Literature DB >> 20169770

Disability and survival of multiple sclerosis in Saskatoon, Saskatchewan.

Walter J Hader1.   

Abstract

BACKGROUND: A population-based prevalent group of 150 clinical definite patients ascertained on 1 January 1977, in Saskatoon, Saskatchewan, was followed for 30 years.
OBJECTIVES: To outline the clinical characteristics, determine the levels of disability at 15, 25, 35, 40, and 45 years after onset, to estimate the survival after onset and life expectancy.
METHODS: Clinical records were maintained, and the cohort reviewed each decade for 30 years. The disability levels according to the Kurtzke Extended Disability Status Scale were recorded and survival times were estimated. SPSS and Kaplan-Meier methods were used for analysis.
RESULTS: On prevalence day, 1 January 1977, there were 48 (32%) men and 102 (68%) women, with an average age of onset of 32.2 +/- 10 years and 28.4 +/- 8.6 years. The average duration of disease was 15.7 years. On 1 January 2007, 39 (26%) patients were living, 105 (70%) deceased, and 6 (4%) were missing The disability levels recorded in 1977 and 2007, at 15 and 45 years after onset, were mild (EDSS < or = 2.5), 33.3% and 8.0%; moderate (EDSS3-5.5), 17.3% and 2.7%; severe (EDSS6-7.5), 6.6% and 4.7%; maximum (EDSS8-9.5), 22.7% and 10.7%. The median survival time after onset was 33 (95% CI: 27.3-38.6) years for men and 38 (95% CI: 34.1-41.9) years for women. The median duration of life was 68.9 years for men and 69.5 years for women, and a decreased life expectancy of 7.7 and 12.8 years.
CONCLUSIONS: Multiple sclerosis is a progressive neurological disorder and long-term survival is associated with moderate to severe disability and decreased life expectancy.

Entities:  

Mesh:

Year:  2010        PMID: 20169770     DOI: 10.1017/s0317167100009616

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  6 in total

Review 1.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 2.  Mortality in patients with multiple sclerosis.

Authors:  Antonio Scalfari; Volker Knappertz; Gary Cutter; Douglas S Goodin; Raymond Ashton; George C Ebers
Journal:  Neurology       Date:  2013-07-09       Impact factor: 9.910

3.  Predictors of Mortality in Veterans with Multiple Sclerosis in an Outpatient Clinic Setting.

Authors:  Meheroz H Rabadi; Christopher E Aston
Journal:  Int J MS Care       Date:  2017 Sep-Oct

4.  Magnetic Resonance Imaging of Spinal Cord Lesions in Patients with Multiple Sclerosis in Saskatchewan, Canada.

Authors:  Aman Saini; Kevin Bach; Ilia Poliakov; Katherine B Knox; Michael C Levin
Journal:  Int J MS Care       Date:  2020-04-14

5.  Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.

Authors:  Emmanuelle Leray; Sandra Vukusic; Marc Debouverie; Michel Clanet; Bruno Brochet; Jérôme de Sèze; Hélène Zéphir; Gilles Defer; Christine Lebrun-Frenay; Thibault Moreau; Pierre Clavelou; Jean Pelletier; Eric Berger; Philippe Cabre; Jean-Philippe Camdessanché; Shoshannah Kalson-Ray; Christian Confavreux; Gilles Edan
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

6.  The prevalence of familial multiple sclerosis in saskatoon, Saskatchewan.

Authors:  Walter J Hader; Irene M Yee
Journal:  Mult Scler Int       Date:  2014-02-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.